Logo

Schering Will Utilize Myriad's ProNet Product

Nov 21, 1998
Premium

SALT LAKE CITY--In a collaboration that Myriad Genetics here values at $51 million, German pharmaceutical company Schering will use Myriad's protein-to-protein interaction technology ProNet to study biochemical pathways of major diseases. In North America, Myriad will have an option to copromote in all new therapeutic products and receive 50 percent of profits from sales of drugs discovered using the technology. Myriad said it will collaborate with Schering scientists to identify drug targets using ProNet to reveal the cascade of protein interactions that lead to major human diseases.

Filed under

Informatics
Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.